Dalcetrapib, aslo known as JTT-705, is a CETP inhibitor. The drug was aimed at raising the blood levels of "good cholesterol" (cholesterol carried in HDL particles, aka HDL-C). Prevailing observations indicate that high HDL levels correlate with better overall cardiovascular health, though it remains unclear whether raising HDL levels consequently leads to an increase in cardiovascular health. Development of this drug was halted on May 7, 2012 “due to a lack of clinically meaningful efficacy.
Related Products:
SRT1720 hcl; Barasertib; ABT-751; MK-5108; SNS-314; SNS-314 mesylate; Alisertib; Abexinostat; Romidepsin; R547; Tubastatin A HCL; SCH900776; PF00477736; GW7647